Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Lack of Assurance of Sterility
Consumers and healthcare providers should stop using this product immediately. Contact Fresenius Kabi Compounding, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Acyclovir Sodium Injection is used for treating viral infections, particularly those caused by herpes viruses. It is commonly administered in hospital settings for patients requiring intravenous antiviral therapy.
The product's lack of assurance of sterility means it could be contaminated, posing a risk of infection upon administration. Sterile conditions are critical for intravenous medications to prevent serious health complications.
This recall is not part of a broader industry pattern.
Consumers and healthcare providers must act quickly to prevent potential health risks from using this non-sterile product. The urgency is heightened given the serious implications of infection from contaminated injections.
The lot number and expiration date can typically be found on the product's outer packaging or label.
Expect a refund processing timeline of approximately 4-6 weeks after returning the product.
Keep a record of your purchase, including receipts and correspondence regarding the recall.
This recall affects Acyclovir Sodium, 200 mg per 100 mL, packaged in single-use bags. The recalled lot number is C274-000049124, with an expiration date of February 28, 2026. The product was distributed nationwide in the United States.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.